A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study ...

Bacillus Calmette-Guérin (BCG) is the main immunotherapy used to treat early-stage bladder cancer. Immunotherapy uses your immune system to fight cancer. BCG is a type of intravesical therapy ...

Radiation therapy. During this therapy, an X-ray, or other type of machine, focuses radiation on your bladder or other area of the body where there is cancer. Radiation can either kill the tumors ...

SAN DIEGO, Calif. (Ivanhoe Newswire) - A breakthrough in bladder cancer treatment is helping to save more lives. The American Cancer Society estimates that 83,000 new cases of bladder cancer will ...

Among patients with non–muscle-invasive bladder cancer, neoadjuvant mitomycin demonstrated favorable ... or recurrent NMIBC who had not received prior adjuvant intravesical therapy. Additional ...

high-risk non-muscle-invasive bladder cancer (HR NMIBC) with a manageable safety profile, primary results from the phase 3 CREST trial show. Sasanlimab has the potential to change the treatment ...

NMIBC is found in the tissue of the inner surface of the bladder and is the tenth most common cancer in the UK with approximately 10,000 people each year diagnosed with the illness.

The CISTO Study (Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer; Clinicaltrials.gov, NCT03933826) was conducted at 36 US academic and community urology ...

The treatment for both non-muscle invasive and invasive bladder cancer is becoming more sophisticated daily as we gain knowledge of the behavior of these cancers, identifying new targets for therapy ...

"Pfizer’s sasanlimab and BCG combo therapy improves EFS in bladder cancer trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this ...